Skip to content


Prevymis (letermovir) is a small molecule pharmaceutical. Letermovir was first approved as Prevymis on 2017-11-08. It has been approved in Europe to treat cytomegalovirus infections. Prevymis's patents are valid until 2033-02-28 (FDA).
Trade Name Prevymis
Common Name Letermovir
Indication cytomegalovirus infections
Drug Class Antivirals
Get full access now